PD-L1 expression in recurrent head and neck squamous cell carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Otorhinolaryngology
Link
https://link.springer.com/content/pdf/10.1007/s00405-021-06777-7.pdf
Reference35 articles.
1. De Costa AM, Young MR (2011) Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs 22(7):674–681. https://doi.org/10.1097/CAD.0b013e328340fd18
2. Kiyota N, Hasegawa Y, Takahashi S et al (2017) A randomized, open-label, phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol 73:138–146. https://doi.org/10.1016/j.oraloncology.2017.07.023.
3. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252
4. Moskovitz JM, Moy J, Seiwert TY, Ferris RL (2017) Immunotherapy for head and neck squamous cell carcinoma: a review of current and emerging therapeutic options. Oncologist 22(6):680–693. https://doi.org/10.1634/theoncologist.2016-0318
5. Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 38(1):90–97. https://doi.org/10.1097/COC.0b013e3182868ec8
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study);Oral Oncology;2024-10
2. The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China;Frontiers in Oncology;2024-02-19
3. Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma;Discover Oncology;2024-01-31
4. Programmed Cell Death Ligand 1 Immunoexpression in Head and Neck Squamous Cell Carcinoma: A Narrative Review of Considerations for the Histopathologist;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024
5. The Histological Background of Recurrence in Laryngeal Squamous Cell Carcinoma: An Insight into the Modifications of Tumor Microenvironment;Cancers;2023-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3